Choose a language and wait for the translated text.
Abivax, which is developing treatments for chronic inflammatory diseases including ulcerative colitis and Crohn's disease, has long been viewed by investors and industry executives as a potential takeover target for larger drugmakers seeking to build their inflammation and immunology businesses.
